Joslin Diabetes Center   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Boston MA United States (1952)

Organization Overview

First Clinical Trial
1993
NCT00594152
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Alessandro Doria | Allison Goldfine | Joslin Diabetes Center | Joslin Diabetes Centre

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 3)

Cardiovascular Diseases (Phase 3)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Nephropathies (Phase 3)

Diabetic Retinopathy (Phase 3)

Edema (Phase 1)

Hypoglycemia (Phase 4)

Inflammation (Phase 3)

Insulin Resistance (Phase 3)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Macular Edema (Phase 3)

Myocardial Ischemia (Phase 3)

Obesity (Phase 2)

Overweight (Phase 3)

Retinal Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 35
  • # of Trial APIs: 27